Company intelligence / Profile preview

Juventas Therapeutics

Cleveland, Ohio, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 2

Overview

JVS‑100 demonstrated safety and preliminary efficacy in Phase I heart failure trial with dose-dependent improvements in quality-of-life and functional endpoints. Phase II trials initiated for both heart failure and critical limb ischemia. The approach leverages SDF‑1 to activate endogenous stem cell repair pathways, promote angiogenesis, and prevent cell death.[6][9] No recent clinical results published.

Therapeutic areas: Cardiovascular
Modalities: Non-viral gene therapy (JVS‑100 encodes SDF‑1)[4][5]Oligonucleotide therapies[1]
Industry: Biotech

Drug pipeline

1 asset

JVS-100

Partnerships

No major pharmaceutical partnerships disclosed; exclusive license from Cleveland Clinic noted.[1]

Beyond the preview

Go deeper on Juventas Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Juventas Therapeutics.

Explore the full profile